{"id":"basiliximab-tacrolimus-mmf-prednisolon","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (bacterial, viral, fungal)"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Malignancy (long-term)"}]},"_chembl":{"chemblId":"CHEMBL1201439","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Basiliximab is a chimeric monoclonal antibody targeting the IL-2 receptor on T cells, blocking early T-cell activation. Tacrolimus inhibits calcineurin, preventing T-cell cytokine production. Mycophenolate mofetil (MMF) inhibits inosine monophosphate dehydrogenase, selectively suppressing lymphocyte proliferation. Prednisolone is a corticosteroid providing broad immunosuppression. Together, these agents provide multi-target immunosuppression to prevent allograft rejection.","oneSentence":"This is a multi-drug immunosuppressive regimen that blocks T-cell activation and proliferation to prevent organ rejection after transplantation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:20:17.515Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute organ rejection in kidney transplant recipients"},{"name":"Prevention of acute organ rejection in other solid organ transplantation"}]},"trialDetails":[{"nctId":"NCT02083991","phase":"PHASE4","title":"Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2013-01","conditions":"Diabetes Mellitus","enrollment":224},{"nctId":"NCT01843348","phase":"PHASE3","title":"12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-27","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":612},{"nctId":"NCT00724022","phase":"PHASE4","title":"Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation","status":"COMPLETED","sponsor":"University Hospital Freiburg","startDate":"2008-06","conditions":"Disorder Related to Renal Transplantation","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Simulect","Advagraf","CellCept","Decortin"],"phase":"marketed","status":"active","brandName":"Basiliximab, Tacrolimus, MMF, Prednisolon","genericName":"Basiliximab, Tacrolimus, MMF, Prednisolon","companyName":"University Hospital Freiburg","companyId":"university-hospital-freiburg","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a multi-drug immunosuppressive regimen that blocks T-cell activation and proliferation to prevent organ rejection after transplantation. Used for Prevention of acute organ rejection in kidney transplant recipients, Prevention of acute organ rejection in other solid organ transplantation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}